Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

benazeprilat

Known as: benezaprilat 
The active metabolite of benazepril, a carboxyl-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Once the… 
National Institutes of Health

Related topics

Related topics

12 relations
Amlodipine 10 MG / Benazepril hydrochloride 20 MG Oral CapsuleAmlodipine 10 MG / Benazepril hydrochloride 20 MG Oral Capsule [Lotrel]Amlodipine 10 MG / Benazepril hydrochloride 40 MG Oral CapsuleAmlodipine 10 MG / Benazepril hydrochloride 40 MG Oral Capsule [Lotrel]
Expand

Broader (4)

Angiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesbenazepril

Narrower (1)

CGS 14831

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats
Objectives Aliskiren is a new renin inhibitor of a novel structural class that has recently been shown to be efficacious in… 
2000
2000
Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.
The pharmacokinetic disposition of benazeprilat, an angiotensin-converting enzyme (ACE) inhibitor (ACEI), was assessed with a… 
  • figure 1
  • figure 2
  • figure 4
  • table 1
  • figure 3
Highly Cited
1997
Highly Cited
1997
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal…
BACKGROUND The goal of this study was to determine the effects of ACE inhibition (ACEI) alone, AT1 angiotensin (Ang) II receptor… 
1995
1995
Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
Plasma pharmacokinetic variables of benazeprilat, the active metabolite of the angiotensin-converting enzyme (ACE) inhibitor… 
Highly Cited
1994
Highly Cited
1994
Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats.
BACKGROUND Coronary artery disease is an important complication of hypertension. Therefore, the effects of antihypertensive… 
  • table 1
  • table 2
  • figure 3
  • table 3
  • figure 4
Highly Cited
1991
Highly Cited
1991
Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury.
The angiotensin-converting enzyme (ACE) inhibitor, benazeprilat and the angiotensin II (Ang II), AT1-specific receptor antagonist… 
Highly Cited
1991
Highly Cited
1991
Prolonged Angiotensin II Antagonism in Spontaneously Hypertensive Rats: Hemodynamic and Biochemical Consequences
The present study examines the effects of prolonged angiotensin II antagonism in spontaneously hypertensive rats by using an… 
  • figure 1
  • figure 3
  • table 1
  • figure 2
  • figure 4
Highly Cited
1990
Highly Cited
1990
Determinants of angiotensin II generation during converting enzyme inhibition.
The reaction of the renin-angiotensin system to acute angiotensin converting enzyme inhibition was investigated in a single-blind… 
  • table 1
  • figure 1
  • table 2
  • figure 3
  • figure 2
Review
1989
Review
1989
Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors.
There is increasing evidence that inhibition of tissue angiotensin converting enzyme (ACE) is important for the pharmacokinetics… 
1989
1989
Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations.
To investigate the pharmacokinetics of benazepril hydrochloride in special populations, single or multiple doses between 5 and 20… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE